LeeSinBio Co., Ltd., a bio venture company in the third cohort of IBK Changgong Daejeon, which researches and develops oral protein new drugs based on synthetic biology, announced that it received the T-5 excellent grade in the technology evaluation review by NICE Information Service Co., Ltd., a technology credit evaluation agency (TCB), and obtained certification as an excellent company.
The technology evaluation by NICE Information Service comprehensively analyzes the technological competitiveness and technology business capabilities possessed by the company, including technology, marketability, business feasibility, and management capabilities, and serves as an index that comprehensively assesses the value of the company's technology.
The technology currently being researched and developed by LeeSinBio is an oral drug delivery system called eLBPs (Engineered Live Biotherapeutic Products), which uses beneficial probiotics as chassis organisms to deliver endolysins, a next-generation super antibiotic new drug substance, to the intestines. According to NICE Information Service's technology evaluation criteria, it received the T-5 grade, which corresponds to the top 5 levels, and obtained approval as an excellent company. This grade is awarded to companies whose technology ranks among the top in the relevant technology field and have future growth potential.
Meanwhile, LeeSinBio was selected as the third cohort of IBK Changgong Daejeon in the first half of this year, an innovation startup nurturing program operated by IBK Industrial Bank of Korea.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
